Literature DB >> 6626008

Amiodarone-induced lens opacities.

A J Flach, B J Dolan, B Sudduth, J Weddell.   

Abstract

Amiodarone hydrochloride is a benzofurane derivative used for cardiac abnormalities. Its use is commonly associated with an asymptomatic keratopathy. Although lipid deposits have been observed with the electron microscope in the lens epithelium of one patient with a history of amiodarone therapy, lens opacities have not been reported in patients using this drug. Visually inconsequential, anterior subcapsular lens opacities in seven of 14 patients using moderate to high doses of amiodarone who were examined at the Veterans Administration Hospital in San Francisco are reviewed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6626008     DOI: 10.1001/archopht.1983.01040020556010

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  5 in total

1.  Progression of amiodarone induced cataracts.

Authors:  A J Flach; B J Dolan
Journal:  Doc Ophthalmol       Date:  1993       Impact factor: 2.379

Review 2.  Clinically important ocular reactions to systemic drug therapy.

Authors:  I G Rennie
Journal:  Drug Saf       Date:  1993-09       Impact factor: 5.606

3.  Amiodarone-induced multiorgan toxicity with ocular findings on confocal microscopy.

Authors:  Ugur Turk; Bengu Gerceker Turk; Suzan Guven Yılmaz; Esref Tuncer; Emin Alioğlu; Tugrul Dereli
Journal:  Middle East Afr J Ophthalmol       Date:  2015 Apr-Jun

4.  Amiodarone-Induced Multi-Systemic Toxicity Involving the Liver, Lungs, Thyroid, and Eyes: A Case Report.

Authors:  Hye-Su You; Jae Hyun Yoon; Sung Bum Cho; Yoo-Duk Choi; Yung Hui Kim; Wonsuk Choi; Ho-Cheol Kang; Sung Kyu Choi
Journal:  Front Cardiovasc Med       Date:  2022-02-28

5.  In Vivo Confocal Microscopic Observations of Vortex Keratopathy in Patients with Amiodarone-Induced Keratopathy and Fabry Disease.

Authors:  Yasuhito Ikegawa; Atsushi Shiraishi; Yasuhito Hayashi; Akiyoshi Ogimoto; Yuichi Ohashi
Journal:  J Ophthalmol       Date:  2018-03-21       Impact factor: 1.909

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.